ATTO 10-K & 10-Q changes, risk factors and insider trading
Attovia Therapeutics, Inc. · Nasdaq · Biological Products, (No Diagnostic Substances) · CIK 2058707 · All filings on SEC.gov
At a glance
What changed in the latest 10-K
Comparison not available: Not available: fewer than two 10-K filings on EDGAR to compare..
What changed in the latest 10-Q
Comparison not available: Not available: fewer than two 10-Q filings on EDGAR to compare (only one so far)..
ATTO insider buying and selling (Form 4)
Since 2026-04-11, insiders reported open-market purchases in 8 Form 4 filings (7 insiders, 2 trade dates, 4,210,587 shares, about $72.9M) and open-market sales in 4 filings (3 insiders, 1 trade date, 423,228 shares, about $9.0M). Net open-market shares: 3,787,359 (purchases minus sales); net value about $63.9M.Totals add up every open-market (code P and S) line in those filings, using the prices reported in the filings. Awards, option exercises, tax withholding and gifts are listed below but not counted.
| Trade date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-08-06 | Walsh Colin |
Open-market purchase | 500,000 | $17.00 | $8.5M |
| 2026-08-06 | Walsh Colin |
Conversion | 1,957,134 | — | — |
| 2026-08-06 | Walsh Colin |
Conversion | 478,498 | — | — |
| 2026-08-06 | Goldman Sachs Asset Management, L.p. |
Conversion | 1,957,134 | — | — |
| 2026-08-06 | Goldman Sachs Asset Management, L.p. |
Conversion | 478,498 | — | — |
| 2026-08-06 | Goldman Sachs Asset Management, L.p. |
Open-market purchase | 500,000 | $17.00 | $8.5M |
| 2026-08-06 | Walsh Colin |
Conversion | 1,957,134 | — | — |
| 2026-08-06 | Walsh Colin |
Conversion | 478,498 | — | — |
| 2026-08-06 | Walsh Colin |
Open-market purchase | 500,000 | $17.00 | $8.5M |
| 2026-08-06 | Goldman Sachs & Co. Llc |
Open-market purchase | 500,000 | $17.00 | $8.5M |
| 2026-08-06 | Goldman Sachs & Co. Llc |
Conversion | 478,498 | — | — |
| 2026-08-06 | Goldman Sachs & Co. Llc |
Conversion | 1,957,134 | — | — |
| 2026-08-06 | Deep Track Biotechnology Master Fund, Ltd. |
Conversion | 1,957,138 | — | — |
| 2026-08-06 | Venbio Global Strategic Fund Iv, L.p. |
Open-market purchase | 382,352 | $17.00 | $6.5M |
| 2026-08-06 | Venbio Global Strategic Fund Iv, L.p. |
Conversion | 821,998 | — | — |
| 2026-08-06 | Venbio Global Strategic Fund Iv, L.p. |
Conversion | 2,311,870 | — | — |
| 2026-08-06 | Venbio Global Strategic Fund Iv, L.p. |
Conversion | 665,147 | — | — |
| 2026-08-06 | Green Jeremy |
Open-market purchase | 200,000 | $17.00 | $3.4M |
| 2026-08-06 | Green Jeremy |
Conversion | 782,854 | — | — |
| 2026-08-06 | Green Jeremy |
Open-market purchase | 400,000 | $17.00 | $6.8M |
| 2026-08-06 | Sanofi |
Conversion | 782,855 | — | — |
| 2026-08-06 | Sanofi |
Open-market purchase | 300,000 | $17.00 | $5.1M |
| 2026-08-06 | Fhmls Xi, L.p. |
Open-market purchase | 588,235 | $17.00 | $10.0M |
| 2026-08-06 | Fhmls Xi, L.p. |
Conversion | 961,322 | — | — |
| 2026-08-06 | Fhmls Xi, L.p. |
Conversion | 1,189,940 | — | — |
| 2026-08-06 | Fhmls Xi, L.p. |
Conversion | 1,590,175 | — | — |
| 2026-08-06 | Fhmls Xi, L.p. |
Conversion | 1,749,192 | — | — |
| 2026-08-05 | Walsh Colin |
Open-market sale | 200 | $22.10 | $4.4K |
| 2026-08-05 | Walsh Colin |
Open-market purchase | 85,000 | $21.00 | $1.8M |
| 2026-08-05 | Walsh Colin |
Open-market sale | 988 | $22.03 | $21.8K |
| 2026-08-05 | Walsh Colin |
Open-market sale | 447 | $21.87 | $9.8K |
| 2026-08-05 | Walsh Colin |
Open-market sale | 1,332 | $22.03 | $29.3K |
| 2026-08-05 | Walsh Colin |
Open-market sale | 200 | $22.05 | $4.4K |
| 2026-08-05 | Walsh Colin |
Open-market sale | 1,556 | $22.06 | $34.3K |
| 2026-08-05 | Walsh Colin |
Open-market sale | 3,402 | $22.02 | $74.9K |
| 2026-08-05 | Walsh Colin |
Open-market sale | 480 | $21.55 | $10.3K |
| 2026-08-05 | Walsh Colin |
Open-market sale | 100 | $22.11 | $2.2K |
| 2026-08-05 | Walsh Colin |
Open-market sale | 753 | $21.97 | $16.5K |
| 2026-08-05 | Walsh Colin |
Open-market sale | 672 | $22.02 | $14.8K |
| 2026-08-05 | Walsh Colin |
Open-market sale | 6,970 | $22.03 | $153.5K |
| 2026-08-05 | Walsh Colin |
Open-market sale | 400 | $22.02 | $8.8K |
| 2026-08-05 | Walsh Colin |
Open-market sale | 1,180 | $21.84 | $25.8K |
| 2026-08-05 | Walsh Colin |
Open-market sale | 1,040 | $22.05 | $22.9K |
| 2026-08-05 | Walsh Colin |
Open-market sale | 300 | $20.84 | $6.3K |
| 2026-08-05 | Walsh Colin |
Open-market sale | 443 | $21.78 | $9.6K |
| 2026-08-05 | Walsh Colin |
Open-market sale | 200 | $22.05 | $4.4K |
| 2026-08-05 | Walsh Colin |
Open-market sale | 700 | $22.07 | $15.4K |
| 2026-08-05 | Walsh Colin |
Open-market sale | 1,163 | $22.19 | $25.8K |
| 2026-08-05 | Walsh Colin |
Open-market sale | 100 | $21.99 | $2.2K |
| 2026-08-05 | Walsh Colin |
Open-market sale | 6,763 | $21.61 | $146.1K |
| 2026-08-05 | Walsh Colin |
Open-market sale | 76,418 | $21.04 | $1.6M |
| 2026-08-05 | Goldman Sachs Asset Management, L.p. |
Open-market sale | 753 | $21.97 | $16.5K |
| 2026-08-05 | Goldman Sachs Asset Management, L.p. |
Open-market sale | 672 | $22.02 | $14.8K |
| 2026-08-05 | Goldman Sachs Asset Management, L.p. |
Open-market sale | 6,970 | $22.03 | $153.5K |
| 2026-08-05 | Goldman Sachs Asset Management, L.p. |
Open-market sale | 400 | $22.02 | $8.8K |
| 2026-08-05 | Goldman Sachs Asset Management, L.p. |
Open-market sale | 1,180 | $21.84 | $25.8K |
| 2026-08-05 | Goldman Sachs Asset Management, L.p. |
Open-market sale | 1,040 | $22.05 | $22.9K |
| 2026-08-05 | Goldman Sachs Asset Management, L.p. |
Open-market sale | 300 | $20.84 | $6.3K |
| 2026-08-05 | Goldman Sachs Asset Management, L.p. |
Open-market sale | 443 | $21.78 | $9.6K |
| 2026-08-05 | Goldman Sachs Asset Management, L.p. |
Open-market sale | 200 | $22.05 | $4.4K |
Well-known investors holding ATTO (13F)
None of the 59 investors we track reported a position in their latest 13F.